Kotra Industries BhdXKLS:0002 84 OCF Margin % is 20.76% as of Mar. 2026, which is 24% below its 10-year median of 27.19. GuruFocus rates XKLS:0002 with a GF Score™ of 84/100 and a GF Value™ of RM4.33 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 959 Drug Manufacturers companies, Kotra Industries Bhd ranks better than 77.37% on this metric.
The historical rank and industry rank for Kotra Industries Bhd's OCF Margin % or its related term are showing as below:
XKLS:0002'
s OCF Margin % Range Over the Past 10 Years
Min: 17.73 Med: 27.19 Max: 32.42
Current: 20.1
During the past 13 years, the highest OCF Margin % of Kotra Industries Bhd was 32.42%. The lowest was 17.73%. And the median was 27.19%.
XKLS:0002's OCF Margin % is ranked better than 77.37% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.94
vs XKLS:0002: 20.10
Kotra Industries Bhd OCF Margin % Related Terms
Kotra Industries Bhd OCF Margin % Historical Data
* Premium members only.
The historical data trend for Kotra Industries Bhd's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0002 vs ZTS, UTHR, VTRS: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kotra Industries Bhd's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kotra Industries Bhd OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kotra Industries Bhd's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Kotra Industries Bhd's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kotra Industries Bhd (XKLS:0002) has a OCF Margin % of 20.76% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kotra Industries Bhd and its competitors. This is 24% below median its historical median of 27.19. Over the past decade, Kotra Industries Bhd's OCF Margin % has ranged from 17.73 to 32.42. According to the industry distribution chart, Kotra Industries Bhd ranks #217 out of 959 companies in the Drug Manufacturers industry, placing it in the top 22.6%.
Is Kotra Industries Bhd's OCF Margin % too high?
Kotra Industries Bhd's current OCF Margin % of 20.76% is 24% below median its 10-year median of 27.19. Over the past 10 years, this metric has ranged from a low of 17.73 to a high of 32.42. The Drug Manufacturers industry median OCF Margin % is 9.94. Kotra Industries Bhd's value of 20.76% is 108.9% above this industry median. Based on the distribution chart, Kotra Industries Bhd ranks #217 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kotra Industries Bhd has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kotra Industries Bhd's OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kotra Industries Bhd ranks #217 out of 959 companies for OCF Margin %. This places Kotra Industries Bhd in the top 23% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.94. Kotra Industries Bhd's value of 20.76% is 108.9% above this benchmark. Historically, Kotra Industries Bhd's own OCF Margin % has ranged from 17.73 to 32.42 over the past decade. While the company's 10-year median is 27.19 vs. the industry median of 9.94, Kotra Industries Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kotra Industries Bhd's current OCF Margin % of 20.76% is 108.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kotra Industries Bhd and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kotra Industries Bhd's current OCF Margin % is 20.76%, which is 24% below median its own 10-year median of 27.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kotra Industries Bhd stock overvalued right now?
Based on GuruFocus' analysis, Kotra Industries Bhd (XKLS:0002) is currently considered Modestly Undervalued. The stock's GF Value™ is RM4.33, compared to a current price of RM3.71 — trading 14.3% below its estimated fair value. The current OCF Margin % is 20.76%, which is 24% below median its 10-year median of 27.19 and 108.9% above the Drug Manufacturers industry median of 9.94. Kotra Industries Bhd's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Kotra Industries Bhd (XKLS:0002), the current OCF Margin % is 20.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kotra Industries Bhd (XKLS:0002) Overvalued in 2026?
Based on GuruFocus' analysis, Kotra Industries Bhd stock appears to be undervalued.
The current stock price of RM3.71 is trading 14.3% below its estimated GF Value™ of RM4.33.
GuruFocus considers Kotra Industries Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0002:
OCF Margin %: 20.76% (24% below median its 10-year median of 27.19)
GF Value™: RM4.33 vs. price of RM3.71 (14.3% below fair value)
Industry Position: 108.9% above the Drug Manufacturers median (#217 of 959)
No single metric tells the full story. See the XKLS:0002 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kotra Industries Bhd is a Malaysian pharmaceutical company engaged in the development, manufacturing, and supply of pharmaceutical and healthcare products supporting all life stages. Its portfolio includes life-saving medicines, OTC supplements, and nutrition products. The Group markets three core brands: Appeton, offering health supplements and nutrition across all age groups; Vaxcel, providing injectable medicines for infectious diseases, kidney care, and gastroenterology; and Axcel, specializing in oral and topical medicines for paediatrics, dermatology, and infectious diseases. The company operates in Malaysia and overseas, with the majority of revenue derived from Malaysia.
84GF Score
Get the complete analysis for XKLS:0002
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0002 has been successfully added to your 
